Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909971 | PMC |
| http://dx.doi.org/10.36660/abc.20200631 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of age, race, and medication use on efficacy endpoints in a randomized controlled trial of topical sildenafil cream for the treatment of female sexual arousal disorder.
Sex Med
October 2024
Daré Bioscience, San Diego, CA, United States.
Background: A study of topical Sildenafil Cream 3.6% was completed among healthy premenopausal women with female sexual arousal disorder.
Aims: To compare efficacy endpoints based on product use in pre-planned and post-hoc subsets of age, race, and medication use.
Sildenafil's effectiveness in the primary coronary slow flow phenomenon: a pilot randomised controlled clinical trial.
Open Heart
August 2024
Yazd Cardiovascular Research Center, Non-communicable Diseases Research Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Article Synopsis
- The study investigates the potential effectiveness of sildenafil in treating primary coronary slow flow phenomenon (CSFP), which can cause severe cardiovascular issues including chest pain and sudden death.
- A 12-week pilot study involved 20 patients who were randomly assigned to receive either 50 mg of sildenafil or a placebo, measuring improvements in angina severity, exercise capacity, and overall heart function.
- Results showed significant improvements in the sildenafil group, with all patients becoming asymptomatic during exercise and notable increases in functional capacity compared to the placebo group, suggesting sildenafil may be a promising treatment for CSFP.
Safety of topical sildenafil cream, 3.6% in a randomized, placebo-controlled trial for the treatment of female sexual arousal disorder.
J Sex Med
September 2024
Daré Bioscience, San Diego, CA 92122, United States.
Background: There are currently no Food and Drug Administration-approved treatments for female sexual arousal disorder (FSAD), which is physiologically analogous to male erectile dysfunction.
Aims: The study sought to test the systemic and local genital safety of topical sildenafil cream, 3.6% (sildenafil cream) among healthy premenopausal women with FSAD and their sexual partners over a 12-week treatment period.
Neurodevelopmental outcomes at 2 years in children who received sildenafil therapy in utero: The STRIDER randomised controlled trial.
BJOG
November 2024
Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
Objective: Severe early-onset fetal growth restriction (FGR) causes stillbirth, neonatal death and neurodevelopmental impairment. Poor maternal spiral artery remodelling maintains vasoactive responsiveness but is susceptible to treatment with sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, which may improve perinatal outcomes.
Design: Superiority, double-blind randomised controlled trial.
Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis.
Eur Heart J Cardiovasc Pharmacother
August 2024
First Cardiology Department, Hippokration Hospital, Athens Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Aims: Phosphodiesterase 5 inhibitors (PDE5i), which are widely used for the treatment of erectile dysfunction (ED), have been found to exhibit systemic vascular benefits by improving endothelial function. In this context, we sought to evaluate the effects of PDE5i on long-term cardiovascular outcomes and mortality.
Methods And Results: A comprehensive search of electronic databases was conducted up to 30 May 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!